Methods Of Selectively Treating Asthma Using IL-13 Antagonists
First Claim
1. A method of selectively treating a patient having asthma, comprisingi) identifying a patient having at least one AIR marker selected from the group consisting of AIR marker-1, 2, 3, 4, 5, 6, 7, 8, and 9, andii) thereafter administering a therapeutically effective amount of an IL-13 antagonist to the patient.
4 Assignments
0 Petitions
Accused Products
Abstract
The disclosure is directed to novel predictive methods and personalized therapies for treating asthma. Specifically, this disclosure relates to methods of treating a patient having asthma by selectively administering an IL-13 antagonist, on the basis of that patient being genetically predisposed to have a favorable response to treatment with the IL-13 antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having asthma will respond to treatment with an IL-13 antagonist.
-
Citations
22 Claims
-
1. A method of selectively treating a patient having asthma, comprising
i) identifying a patient having at least one AIR marker selected from the group consisting of AIR marker-1, 2, 3, 4, 5, 6, 7, 8, and 9, and ii) thereafter administering a therapeutically effective amount of an IL-13 antagonist to the patient.
-
3. (canceled)
-
7. A method of predicting the likelihood that a patient having asthma will respond to treatment with an IL-13 antagonist, comprising the step of assaying a biological sample from the patient for the presence or absence of at least one AIR marker selected from the group consisting of AIR marker-1, 2, 3, 4, 5, 6, 7, 8, and 9, wherein:
-
a) the presence of the at least one AIR marker is indicative of an increased likelihood that the patient will respond to treatment with the IL-13 antagonist; and b) the absence of the at least one AIR marker is indicative of a decreased likelihood that the patient will respond to treatment with the IL-13 antagonist. - View Dependent Claims (14)
-
-
8. (canceled)
-
9. A method of predicting the likelihood that a patient having asthma will respond to treatment with an IL-13 antagonist, comprising the steps of:
-
a) assaying a biological sample from the patient for the presence or absence of at least one AIR marker, and b) determining whether said AIR marker is present in homozygous or heterozygous form, wherein the presence of the at least one AIR marker in homozygous form is indicative of an increased likelihood that the patient will respond to treatment with the IL-13 antagonist, wherein said at least one AIR marker is selected from the group consisting of; i) AIR marker 3 and AIR marker 7 each present in homozygous form, ii) AIR marker 3 present in homozygous form and AIR marker 7 in heterozygous form, a. AIR marker 7 present in homozygous form and AIR marker 3 in heterozygous form, and b. AIR marker 3 in homozygous form.
-
Specification